Delta Lloyd Asset Management N.V. acquired a new position in Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 23,503 shares of the biotechnology company’s stock, valued at approximately $6,378,000.

Other institutional investors have also modified their holdings of the company. Wrapmanager Inc. grew its position in Biogen by 7.7% in the first quarter. Wrapmanager Inc. now owns 5,525 shares of the biotechnology company’s stock worth $1,511,000 after acquiring an additional 396 shares during the period. Savant Capital LLC grew its position in Biogen by 3.7% in the first quarter. Savant Capital LLC now owns 846 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 30 shares during the period. Botty Investors LLC grew its position in Biogen by 75.0% in the second quarter. Botty Investors LLC now owns 11,232 shares of the biotechnology company’s stock worth $3,048,000 after acquiring an additional 4,812 shares during the period. Vanguard Group Inc. grew its position in Biogen by 2.4% in the first quarter. Vanguard Group Inc. now owns 14,352,490 shares of the biotechnology company’s stock worth $3,924,258,000 after acquiring an additional 342,568 shares during the period. Finally, BB&T Securities LLC grew its position in Biogen by 25.0% in the second quarter. BB&T Securities LLC now owns 12,989 shares of the biotechnology company’s stock worth $3,524,000 after acquiring an additional 2,598 shares during the period. Institutional investors own 87.26% of the company’s stock.

Several brokerages recently weighed in on BIIB. UBS AG reiterated a “neutral” rating and issued a $285.00 price objective (up from $270.00) on shares of Biogen in a research report on Wednesday, July 26th. Sanford C. Bernstein reiterated an “outperform” rating on shares of Biogen in a research report on Thursday, May 25th. Vetr lowered Biogen from a “strong-buy” rating to a “buy” rating and set a $311.67 price objective for the company. in a research report on Wednesday, June 21st. Goldman Sachs Group, Inc. (The) upgraded Biogen from a “buy” rating to a “conviction-buy” rating and set a $338.00 price objective for the company in a research report on Wednesday, August 16th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $319.00 price objective (up from $315.00) on shares of Biogen in a research report on Wednesday, July 26th. Twelve research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $333.87.

In other Biogen news, EVP Susan H. Alexander sold 7,758 shares of the business’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $285.00, for a total value of $2,211,030.00. Following the transaction, the executive vice president now owns 27,232 shares in the company, valued at approximately $7,761,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Susan H. Alexander sold 4,974 shares of the business’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $290.01, for a total transaction of $1,442,509.74. Following the completion of the transaction, the executive vice president now owns 22,258 shares in the company, valued at approximately $6,455,042.58. The disclosure for this sale can be found here. Insiders own 0.32% of the company’s stock.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/14/delta-lloyd-asset-management-n-v-acquires-shares-of-23503-biogen-inc-biib.html.

Biogen Inc. (BIIB) opened at 324.05 on Thursday. Biogen Inc. has a one year low of $244.28 and a one year high of $330.00. The stock has a market cap of $68.51 billion, a price-to-earnings ratio of 21.26 and a beta of 0.77. The firm’s 50 day moving average price is $295.86 and its 200 day moving average price is $277.45.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Tuesday, July 25th. The biotechnology company reported $5.04 EPS for the quarter, topping analysts’ consensus estimates of $4.36 by $0.68. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. During the same quarter in the previous year, the business posted $5.21 EPS. The firm’s revenue was up 6.4% compared to the same quarter last year. Equities analysts forecast that Biogen Inc. will post $21.44 earnings per share for the current year.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Stock Ratings for Biogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc. and related stocks with our FREE daily email newsletter.